Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Summary
This study evaluates how well panitumumab-IRDye800 and 89Zr-panitumumab work in identifying cancer that has spread to the lymph nodes in patients with squamous cell head and neck cancer. Panitumumab-IRDye800 is a drug that contains a dye molecule that fluoresces during surgery to indicate cancerous tissue. 89Zr-panitumumab is a drug that contains a small amount of radiation, which makes it visible in positron emission tomography (PET) scans. PET scans make detailed, computerized pictures of areas inside the body where the drug is used. Giving panitumumab-IRDye800 and 89Zr-panitumumab to patients with head and neck cancer may help doctors find metastatic lymph nodes better than current methods \[positron emission tomography (PET); computed tomography (CT); magnetic imaging resonance (MRI), or combinations\].
Timeline
- Start
- 2019-01-07
- Primary completion
- 2020-12-11
- Completion
- 2021-08-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 89-Zirconium (Zr-89) Panitumumab | Diagnostic / imaging agent | 29 mbq | Intravenous |
| Subject | 89-Zirconium (Zr-89) Panitumumab | Diagnostic / imaging agent | 45 mbq | Intravenous |
| Subject | Panitumumab-IRDye800 | Diagnostic / imaging agent | 30 mg | Intravenous |